Highly Multiplexed Cell-Based GPCR Assay.

项目总结/摘要 基于芯片的技术--例如DNA微阵列和下一代测序-- 大大加快了生物医学发现的步伐，因为它们是微型的， 多路复用，高度可扩展。我们将把这些相同的优点带到基于细胞的 针对GPCR进行筛查，GPCR是治疗精神分裂症的治疗药物的最常见靶点， 通过应用SpectraGenetics的FAP技术， 到印刷的反向转染微阵列。 新的检测系统将并行检测和量化许多GPCR的反应 通过询问表达FAP标记的阵列反向转染的哺乳动物细胞， 受体。这种小型化、多路复用和可扩展的系统将使多样化的气相化学还原成为可能。 发现项目，并将大大降低每个目标的成本， 二次药物筛选，从而缓解新药开发的主要瓶颈 治疗分子

Project Summary/Abstract Chip-based technologies - e.g. DNA microarrays and next generation sequencing - have profoundly accelerated the pace of biomedical discovery because they are miniaturized, multiplexed, and highly scalable. We will bring these same virtues to cell-based screening against GPCRs, the most prevalent targets of therapeutic drugs to treat mental illness and other diseases and conditions, by applying SpectraGenetics' FAP technology to printed reverse transfection microarrays. The new assay system will detect and quantify the responses of many GPCRs in parallel by interrogating arrayed reverse-transfected mammalian cells that express FAP-tagged receptors. This miniaturized, multiplexed and scalable system will enable diverse GPCR discovery projects, and will dramatically lower the cost-per-target in primary and secondary drug screens, thereby relieving major bottlenecks in the development of new therapeutic molecules.